Skip to main content

Table 4 Laboratory results at baseline and at the end of treatment in relation to treatment outcome

From: Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

Outcome Non-responders
n = 3
Relapsers
n = 3
Responders
n = 92
Intolerant
n = 9
P value
Laboratory result
Hemoglobin (HGB) concentration (gm/dl) Baseline 13.3 ± 2.3 12.73 ± 1.11 12.17 ± 1.6 11.36 ± 1.32 P = 0.26
End of treatment 12.07 ± 0.31 12.13 ± 0.38 11.2 ± 1.5   P = 0.36
White blood cell count (WBCs) (*103/μl) Baseline 3.3 ± 0.36 5.7 ± 2.1A 4.66 ± 1.6B 3.26 ± 1.12AB P = 0.02
End of treatment 3.67 ± 0.23 5.0 ± 1.8 4.65 ± 1.7   P = 0.58
platelet count (PLTs) (*103/μl) Baseline 58 (58–100) 84 (74–111) 94.5 (50–356) 111 (55–142) P = 0.39
End of treatment 57 (43–138) 105 (100–170) 104 (37–392)   P = 0.32
Serum creatinine (mg/dl) Baseline 0.6 ± 0.1A 0.87 ± 0.4 0.85 ± 0.25B 1.17 ± 0.4AB P = 0.003
End of treatment 0.78 ± 0.09 0.85 ± 0.07 0.89 ± 0.37   P = 0.86
ALT/ULN (folds) Baseline 1.05 (0.78–4.12) 1.03 (0.8–1.24) 1.325 (0.22–5.35) 0.93 (0.48–2.85) P = 0.13
End of treatment 0.4 (0.4–1.29) 1.0 (0.88–1.05) 0.67 (0.2-2)   P = 0.13
AST/ULN (folds) Baseline 1.62 (1.03–4.7) 1.85 (1.38–3.41) 1.765 (0.46–5.85) 1.73 (0.4–3.46) P = 0.9
End of treatment 0.55 (0.48–2.27) 0.86 (0.6–1.43) 0.9 (0.25–7)   P = 0.77
Albumin level (gm/dl) Baseline 3.0 ± 0.26 2.53 ± 0.25 2.89 ± 0.4 2.8 ± 0.24 P = 0.32
End of treatment 3.5 ± 0.2 3.1 ± 0.14 3.23 ± 0.48   P = 0.87
Serum bilirubin (mg/dl) Baseline 1.77 ± 0.6 2.3 ± 0.79 1.42 ± 0.7 1.54 ± 1.0 P = 0.23
End of treatment 1.35 ± 0.07 2.13 ± 1.07 1.29 ± 0.7   P = 0.17
I.N.R. Baseline 1.42 ± 0.28 1.42 ± 0.14 1.32 ± 0.22 1.3 ± 0.18 P = 0.72
End of treatment 1.39 ± 0.15 1.32 ± 0.0 1.38 ± 0.25   P = 0.97
AFP (μg/l) Baseline 12.0 (6.5–83) 10.2 (9.0–20.7) 12.35 (0.1–201) 7.6 (2.64–25) P = 0.51
End of treatment 4.8 (4.8–4.8) 8.15 (6.7–9.6) 5.7 (0.2–24)   P = 0.49